ciprofloxacin has been researched along with imatinib mesylate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bai, F; Chen, Y; Ding, Y; Guo, X; Jiang, S; Kuang, B; Li, CQ; Li, J; Li, L; Liu, J; Liu, Y; Wang, J; Wang, L; Xia, B; Yang, G; Zhang, Q; Zhu, XY | 1 |
| Ângelo, S; Moreira, JN; Pinto, AC; Simões, S | 1 |
| Burke, NS; Dassanayake, S; Mealey, KL | 1 |
4 other study(ies) available for ciprofloxacin and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Total Syntheses and Biological Activities of Vinylamycin Analogues.
Topics: Animals; Anti-Infective Agents; Apoptosis; Bacterial Proteins; Depsipeptides; Heterografts; Humans; K562 Cells; Zebrafish | 2017 |
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mitoxantrone; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Pyrimidines; Vinblastine | 2011 |
Tyrosine kinase inhibitors enhance ciprofloxacin-induced phototoxicity by inhibiting ABCG2.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Ciprofloxacin; Dermatitis, Phototoxic; Drug Synergism; Flow Cytometry; Gefitinib; Gene Expression Regulation; HEK293 Cells; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk Factors | 2014 |